Inflammatory Bowel Diseases
Conditions
Brief summary
: Inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC) need long term treatments which can conflict with a desire of pregnancy in women. Uncontrolled IBD increases the risk of poor pregnancy outcomes \[1\]. Antitumor Necrosis Factor α (antiTNFα) are commonly used, off-label, in pregnancy but with the risk of treatment-related complications. Existing recommendations on the use of antiTNFα during pregnancy are conflicting and only rely on expert opinions. This study was aimed to assess appropriateness and risk to benefit ratio of antiTNFα treatment during pregnancy in women with IBD, for both the mother and the baby until the end of the first year.
Interventions
OTHERtreated by antiTNFα
pregnant IBD women treated by antiTNFα
OTHERnot treated by antiTNFα
pregnant IBD women not treated by antiTNFα
Sponsors
Centre Hospitalier Universitaire Dijon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
15 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* pregnancy between 01/01/2011 and 31/12/2014 * Diagnosis of IBD (Crohn's disease or Ulcerative Colitis)
Exclusion criteria
* Non IBD indication of antiTNFα treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall complications | 9 months | composite criteria composed by: * Disease related complications * Treatment related complications * Pregnancy related complications |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Infectious Complications in the children born from IBD mothers | The first year of life | Occurrence of infectious complications during the first year of life |
Countries
France
Outcome results
None listed